Literature DB >> 27495001

15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting.

Matthew Mossanen1, Sarah Holt2, John L Gore2, Daniel W Lin2, Jonathan L Wright2.   

Abstract

BACKGROUND: Penile cancer remains a rare disease in the United States, and its understanding may be limited by the uncommon nature of the malignancy. We sought to describe recent penile cancer treatment patterns using the National Cancer Data Base.
METHODS: A retrospective review of data obtained from the National Cancer Data Base from 1998 to 2012 was performed. We obtained demographic information and therapeutic approaches within the following2 clinical scenarios: performance of partial penectomy for early stage disease (clinical Ta-T2) and the use of chemotherapy for metastatic disease. Multivariate logistic analysis was performed.
RESULTS: A total of 2,677 patients presented with early stage penile carcinoma. The proportion receiving partial penectomy increased from 74% in 1998 to 2000 to 80% in 2010 to 2012 (P<0.001). Partial penectomy was more common in the elderly (age>80, odd ratios [OR] = 1.53, 95% CI: 1.05-2.23), young (age<50, OR = 1.46, 95% CI: 1.02-2.07), and in African Americans (OR = 1.45, 95% CI: 1.00-2.12). Increasing tumor size was significantly associated with decreased likelihood of receiving partial penectomy. Of those presenting with metastatic disease (n = 819), use of chemotherapy increased over the time period from 39% receiving chemotherapy in 1998 to 2000 to 49% in 2010 to 2012 (P<0.03). Patients least likely to receive chemotherapy were older and with higher Comorbidity score (both P<0.05), African American (OR = 0.46, 95% CI: 0.30-0.73), and living≥50 miles from the nearest treatment hospital (OR = 0.37, 95% CI: 0.25-0.55).
CONCLUSIONS: Penile-sparing surgery for early stage disease and the use of chemotherapy for metastatic disease are becoming more commonly utilized over the past several years. Further work is needed to define clinical and nonclinical factors associated with the treatment. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; National Cancer Data Base; Partial penectomy; Penile cancer; United States

Mesh:

Year:  2016        PMID: 27495001     DOI: 10.1016/j.urolonc.2016.06.019

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Penile cancer: Welcome changes in disease management and remaining challenges.

Authors:  Ben Ayres; Nick Watkin
Journal:  Nat Rev Urol       Date:  2016-10-31       Impact factor: 14.432

2.  Chemotherapy Utilization in Men with Advanced Penile Cancer.

Authors:  Edward Chang; Sarah Holt; Bruce Montgomery; Jonathan Wright
Journal:  Urol Pract       Date:  2021-10-15

3.  Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis.

Authors:  Maria T Bourlon; Haydee Verduzco-Aguirre; Elizabeth Molina; Elisabeth Meyer; Elizabeth Kessler; Simon P Kim; Philippe E Spiess; Thomas Flaig
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

4.  Radical penectomy, a compromise for life: results from the PECAD study.

Authors:  Jamil Ghahhari; Michele Marchioni; Philippe E Spiess; Juan J Chipollini; Peter Nyirády; Judith Varga; Pasquale Ditonno; Stefano Boccasile; Giulia Primiceri; Cosimo De Nunzio; Giorgia Tema; Andrea Tubaro; Alessandro Veccia; Alessandro Antonelli; Gennaro Musi; Ottavio De Cobelli; Andrea Conti; Stefano Puliatti; Salvatore Micali; Mario Álvarez-Maestro; José Quesada Olarte; Erico Diogenes; Marcos Venicio Alves Lima; Andrew Tracey; Georgi Guruli; Riccardo Autorino; Petros Sountoulides; Roman Sosnowski; Luigi Schips; Luca Cindolo
Journal:  Transl Androl Urol       Date:  2020-06

5.  Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer.

Authors:  Edward K Chang; Rishi R Sekar; Sarah K Holt; John L Gore; Jonathan L Wright; Yaw A Nyame
Journal:  Urol Pract       Date:  2021-05-01

6.  Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.

Authors:  Hellen Kuasne; Mateus C Barros-Filho; Ariane Busso-Lopes; Fábio A Marchi; Maisa Pinheiro; Juan J M Muñoz; Cristovam Scapulatempo-Neto; Eliney F Faria; Gustavo C Guimarães; Ademar Lopes; José C S Trindade-Filho; Maria Aparecida C Domingues; Sandra A Drigo; Silvia R Rogatto
Journal:  Oncotarget       Date:  2017-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.